Use of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors in Pulmonary Hypertension.

Fiche publication

Date publication

décembre 2025

Journal

Circulation. Heart failure

Auteurs

Membres identifiés du Cancéropôle Est :
Pr SCHINI-KERTH Valérie

Tous les auteurs :
Aguado B, Ruffenach G, Lacoste-Palasset T, Görlach A, Riou M, Gourmelon M, Bauer F, Humbert M, Schini-Kerth V, Vachiéry JL, Montani D, Antigny F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41347317

Résumé

Inhibiting SGLT2 (sodium-glucose cotransporter 2) has recently transformed the medical care of patients with left heart disease. Right ventricular failure is a major predictor for patients suffering from pulmonary hypertension of various causes, including those with postcapillary pulmonary hypertension due to left heart disease. Similar to how SGLT2 inhibition benefits patients with left heart failure, recent studies have suggested utilizing these molecules to enhance right ventricular function in pulmonary hypertension. In this review, we summarize the current knowledge on the use of SGLT2is (SGLT2 inhibitors) in pulmonary hypertension. Further dedicated trials are necessary to establish their role in right ventricular pulmonary vascular disease.